U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula 2Cl.Cu
Molecular Weight 134.452
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of CUPRIC CHLORIDE ANHYDROUS

SMILES

[Cl-].[Cl-].[Cu++]

InChI

InChIKey=ORTQZVOHEJQUHG-UHFFFAOYSA-L
InChI=1S/2ClH.Cu/h2*1H;/q;;+2/p-2

HIDE SMILES / InChI

Molecular Formula ClH
Molecular Weight 36.461
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula Cu
Molecular Weight 63.546
Charge 2
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Sources: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a84d61a4-8e7f-4be1-aba6-f633b334aafc | http://www.sciencedirect.com/science/article/pii/S0167488912000158https://www.ncbi.nlm.nih.gov/pubmed/16971307DOI: 10.1107/s0567740869001725 Retrived from http://scripts.iucr.org/cgi-bin/paper?S0567740869001725https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?fr=522.518 | http://www.worldofchemicals.com/chemicals/chemical-properties/cupric-glycinate.htmlhttps://www.ncbi.nlm.nih.gov/pubmed/8556785 | https://www.ncbi.nlm.nih.gov/pubmed/2135524https://www.ncbi.nlm.nih.gov/pubmed/15704330 | https://www.ncbi.nlm.nih.gov/pubmed/12425037 | https://www.ncbi.nlm.nih.gov/pubmed/1599240 | http://www.certisusa.com/pdf-labels/Kocide3000_label.pdf | http://www.pesticideinfo.org/Detail_Chemical.jsp?Rec_Id=PC33524http://www.emdmillipore.com/US/en/product/Copper-di-ammonium-Titriplex-solution,MDA_CHEM-105217http://www.drugfuture.com/chemdata/tetraamminecopper-sulfate.html | https://cameochemicals.noaa.gov/chemical/3026https://www3.epa.gov/pesticides/chem_search/ppls/019713-00509-20110705.pdfhttp://fs1.agrian.com/pdfs/CORE_7.5_Copper_EDTA_Label.pdfhttps://www.ncbi.nlm.nih.gov/pubmed/6526221http://www.ema.europa.eu/docs/en_GB/document_library/Maximum_Residue_Limits_-_Report/2009/11/WC500013010.pdfhttps://www.ncbi.nlm.nih.gov/pubmed/24106015 | https://www.ncbi.nlm.nih.gov/pubmed/20942456http://www.drugfuture.com/chemdata/schweizer-s-reagent.html | http://pubs.acs.org/doi/abs/10.1021/ed062p878?journalCode=jceda8 | http://pubs.acs.org/doi/abs/10.1021/ed019p356
Curator's Comment: description was created based on several sources, including https://www.copper.org/resources/properties/compounds/other_compounds.html | http://www.vitamins-supplements.org/dietary-minerals/copper.php | https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=bea888b4-9cc6-49da-89e6-5c273b974ed1

Tetraamminecopper dihydroxide also known as Schweizer's Reagent dissolves cellulose; used in rayon production.

CNS Activity

Curator's Comment: Known to be CNS active in zebrafish. Human data not available.

Originator

Sources: http://pubs.acs.org/doi/abs/10.1021/ja01512a012Schweizer, J. Prakt. Chem. 72, 109, 344 (1857).
Curator's Comment: http://www.drugfuture.com/chemdata/schweizer-s-reagent.html

Approval Year

Targets

Targets

Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Preventing
Unknown

Approved Use

Unknown
Preventing
Unknown

Approved Use

Unknown
Preventing
Cupric glycinate

Approved Use

Indications for use. For beef calves and beef cattle for the prevention of copper deficiency, or when labeled for veterinary prescription use, for the prevention and/or treatment of copper deficiency alone or in association with molybdenum toxicity.
Primary
COPPER•MAX

Approved Use

Unknown
Primary
Unknown

Approved Use

Unknown
Preventing
Unknown

Approved Use

Unknown
Primary
Unknown

Approved Use

Unknown
Diagnostic
Unknown

Approved Use

Unknown
Preventing
COPPER

Approved Use

Copper 0.4 mg/mL (Cupric Chloride Injection, USP) is indicated for use as a supplement to intravenous solutions given for total parenteral nutrition (TPN). Administration helps to maintain copper serum levels and to prevent depletion of endogenous stores and subsequent deficiency symptoms.
Preventing
COPINOX

Approved Use

Copinox 4g is indicated for the prevention and treatment of copper deficiency in cattle and sheep.
PubMed

PubMed

TitleDatePubMed
The effect of various fluoride compounds on the development of experimental root surface caries in hamsters.
1995 Dec
Copper Fluoride Luminescence during UV Photofragmentation of Bis(1,1,1,5,5,5-hexafluoro-2,4-pentanedionato)copper(II) in the Gas Phase.
1996 Aug 14
Direct catalytic aldol-type reactions using RCH2CN.
2003 Aug 21
Cu(II) acetate- and Mn(III) acetate-mediated radical reactions of [60]fullerene with ketonic compounds.
2005 Mar 7
A spectroscopic and thermoanalytical study of the mineral hoganite.
2007 May
Synthesis and structural investigation of mono- and polynuclear copper complexes of 4-ethyl-1-(pyridin-2-yl) thiosemicarbazide.
2008 Nov 1
Copper(II) acetate-catalyzed addition of arylboronic acids to aromatic aldehydes.
2009 Jan 16
Copper oxide nanoparticles induce oxidative stress and cytotoxicity in airway epithelial cells.
2009 Oct
Generation of oxidant response to copper and iron nanoparticles and salts: Stimulation by ascorbate.
2009 Oct 30
Regulation of plasminogen activator inhibitor-1 expression in endothelial cells with exposure to metal nanoparticles.
2010 May 19
A chelator-free multifunctional [64Cu]CuS nanoparticle platform for simultaneous micro-PET/CT imaging and photothermal ablation therapy.
2010 Nov 3
Zinc prevents the copper-induced damage of cultured astrocytes.
2010 Oct
Copper sulfide nanoparticles for photothermal ablation of tumor cells.
2010 Oct
Anti-ovulatory activity of H2 receptor blockers in albino rabbits--a preliminary study.
2011 Apr
Molecular responses of human lung epithelial cells to the toxicity of copper oxide nanoparticles inferred from whole genome expression analysis.
2011 Dec 27
Zeta potential and solubility to toxic ions as mechanisms of lung inflammation caused by metal/metal oxide nanoparticles.
2012 Apr
Protective effect of sulphoraphane against oxidative stress mediated toxicity induced by CuO nanoparticles in mouse embryonic fibroblasts BALB 3T3.
2012 Feb
Evaluation of topically applied copper(II) oxide nanoparticle cytotoxicity in human skin organ culture.
2013 Feb
Design, synthesis, antioxidant, and anti-breast cancer activities of novel diethyl(alkyl/aryl/heteroarylamino)(4-(pyridin-2-yl)phenyl)methylphosphonates.
2013 May
Interference of CuO nanoparticles with metal homeostasis in hepatocytes under sub-toxic conditions.
2014
Synthesis and biomedical applications of copper sulfide nanoparticles: from sensors to theranostics.
2014 Feb 26
Electron induced surface reactions of organometallic metal(hfac)₂ precursors and deposit purification.
2014 Jun 11
Unusual 4-arsonoanilinium cationic species in the hydrochloride salt of (4-aminophenyl)arsonic acid and formed in the reaction of the acid with copper(II) sulfate, copper(II) chloride and cadmium chloride.
2017 Apr 1
Ultrasonic energy enhanced the efficiency of advance extraction methodology for enrichment of trace level of copper in serum samples of patients having neurological disorders.
2017 Jul
Comparison of the efficacy of a commercial footbath product with copper sulfate for the control of digital dermatitis.
2017 Jul
Folic acid-modified and functionalized CuS nanocrystal-based nanoparticles for combined tumor chemo- and photothermal therapy.
2017 Jun
Amino acid-mediated 'turn-off/turn-on' nanozyme activity of gold nanoclusters for sensitive and selective detection of copper ions and histidine.
2017 Jun 15
Effects of Excess Copper Ions on Decidualization of Human Endometrial Stromal Cells.
2017 May
Patents

Sample Use Guides

In Vivo Use Guide
Copper 0.4 mg/mL (Cupric Chloride Injection) contains 0.4 mg copper/mL and is administered intravenously only after dilution. The additive should be diluted in a volume of fluid not less than 100 mL. For the adult receiving total parenteral nutrition, the suggested additive dosage is 0.5 to 1.5 mg copper/day (1.25 to 3.75 mL/day). For pediatric patients, the suggested additive dosage is 20 mcg copper/kg/day (0.05 mL/kg/day). Infants weighing less than 1500 gm may have increased requirements because of their low body reserves and increased requirements for growth.
Route of Administration: Intravenous
Human Endometrial Stromal Cells were treated with non-toxic concentrations of copper ions (0-250 uM). mRNA expressions of insulin-like growth factor binding protein (IGFBP-1), prolactin (PRL), Mn-SOD, and FOXO1 were down-regulated during decidualization following the treatments with 100 or 250 uM copper ions. Meanwhile, the amount of malonaldehyde in the supernatant of cells was increased.
Substance Class Chemical
Created
by admin
on Fri Dec 15 16:20:24 UTC 2023
Edited
by admin
on Fri Dec 15 16:20:24 UTC 2023
Record UNII
P484053J2Y
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
CUPRIC CHLORIDE ANHYDROUS
HSDB  
Common Name English
COPPER(II) CHLORIDE
Systematic Name English
NSC-165706
Code English
CUPRIC CHLORIDE [MI]
Common Name English
Copper chloride [WHO-DD]
Common Name English
COPPER CHLORIDE (CUCL2)
Common Name English
COPPER(2+) CHLORIDE
Systematic Name English
COPPER CHLORIDE
WHO-DD  
Systematic Name English
CUPRIC CHLORIDE ANHYDROUS [HSDB]
Common Name English
Code System Code Type Description
MERCK INDEX
m3893
Created by admin on Fri Dec 15 16:20:25 UTC 2023 , Edited by admin on Fri Dec 15 16:20:25 UTC 2023
PRIMARY Merck Index
SMS_ID
100000079804
Created by admin on Fri Dec 15 16:20:25 UTC 2023 , Edited by admin on Fri Dec 15 16:20:25 UTC 2023
PRIMARY
HSDB
259
Created by admin on Fri Dec 15 16:20:25 UTC 2023 , Edited by admin on Fri Dec 15 16:20:25 UTC 2023
PRIMARY
CAS
7447-39-4
Created by admin on Fri Dec 15 16:20:25 UTC 2023 , Edited by admin on Fri Dec 15 16:20:25 UTC 2023
PRIMARY
PUBCHEM
24014
Created by admin on Fri Dec 15 16:20:25 UTC 2023 , Edited by admin on Fri Dec 15 16:20:25 UTC 2023
PRIMARY
EVMPD
SUB13456MIG
Created by admin on Fri Dec 15 16:20:25 UTC 2023 , Edited by admin on Fri Dec 15 16:20:25 UTC 2023
PRIMARY
NSC
165706
Created by admin on Fri Dec 15 16:20:25 UTC 2023 , Edited by admin on Fri Dec 15 16:20:25 UTC 2023
PRIMARY
WIKIPEDIA
Copper(II) chloride
Created by admin on Fri Dec 15 16:20:25 UTC 2023 , Edited by admin on Fri Dec 15 16:20:25 UTC 2023
PRIMARY
DAILYMED
P484053J2Y
Created by admin on Fri Dec 15 16:20:25 UTC 2023 , Edited by admin on Fri Dec 15 16:20:25 UTC 2023
PRIMARY
ECHA (EC/EINECS)
231-210-2
Created by admin on Fri Dec 15 16:20:25 UTC 2023 , Edited by admin on Fri Dec 15 16:20:25 UTC 2023
PRIMARY
CHEBI
49553
Created by admin on Fri Dec 15 16:20:25 UTC 2023 , Edited by admin on Fri Dec 15 16:20:25 UTC 2023
PRIMARY
DRUG BANK
DB09131
Created by admin on Fri Dec 15 16:20:25 UTC 2023 , Edited by admin on Fri Dec 15 16:20:25 UTC 2023
PRIMARY
RXCUI
150596
Created by admin on Fri Dec 15 16:20:25 UTC 2023 , Edited by admin on Fri Dec 15 16:20:25 UTC 2023
PRIMARY RxNorm
EPA CompTox
DTXSID7040449
Created by admin on Fri Dec 15 16:20:25 UTC 2023 , Edited by admin on Fri Dec 15 16:20:25 UTC 2023
PRIMARY
CHEBI
53472
Created by admin on Fri Dec 15 16:20:25 UTC 2023 , Edited by admin on Fri Dec 15 16:20:25 UTC 2023
PRIMARY
FDA UNII
P484053J2Y
Created by admin on Fri Dec 15 16:20:25 UTC 2023 , Edited by admin on Fri Dec 15 16:20:25 UTC 2023
PRIMARY
Related Record Type Details
LABELED -> NON-LABELED
SOLVATE->ANHYDROUS
PARENT -> SALT/SOLVATE
Related Record Type Details
ACTIVE MOIETY